Articles
Retatrutide (GLP-3) Research & Information
The definitive resource on retatrutide — the next-generation triple agonist weight loss drug. Research-backed, regularly updated, and independent.
Explore articles
What Is Retatrutide (GLP-3)?
The world's first triple agonist weight loss drug — how it works, what the trials show, and why people call it GLP-3.
Updated February 2026
Retatrutide Clinical Trials & Results
Living tracker of all retatrutide trials — Phase 1 through the TRIUMPH Phase 3 program.
Updated February 2026
Retatrutide FDA Approval Timeline
Confirmed and projected milestones on retatrutide's path to FDA approval.
Updated February 2026
Retatrutide vs Mounjaro vs Ozempic
How the three generations of weight loss drugs compare — single, dual, and triple agonists.
Updated February 2026
Retatrutide Side Effects & Safety
Clinical trial safety data, the new dysesthesia signal, and how side effects compare to existing GLP-1 drugs.
Updated February 2026
Retatrutide Cost & How to Get It
What retatrutide might cost, how to access it through clinical trials, and why gray market peptides are dangerous.
Updated March 2026
Retatrutide vs Mazdutide: Triple vs Dual Agonist Compared
How the triple agonist retatrutide compares to the dual agonist mazdutide on weight loss, diabetes, and liver fat data.
Updated February 2026
Retatrutide Dosage & Dosing Guide
How retatrutide is dosed in clinical trials — titration schedule, dose levels, and what each dose achieved.
Updated February 2026
Retatrutide vs Survodutide
Two next-generation obesity drugs that both include glucagon agonism — how the triple and dual agonist approaches compare.
Updated February 2026
Retatrutide and Alcohol: What We Know
No direct studies exist on retatrutide and alcohol, but GLP-1 receptor agonist research points to reduced intake and liver effects.
Updated February 2026
GLP-1 vs GLP-2 vs GLP-3: What's the Difference?
GLP-1 and GLP-2 are real hormones. "GLP-3" is not — it's slang for retatrutide. Here's what each term actually means.
Updated February 2026
Retatrutide News & Updates
Every retatrutide development tracked chronologically. Updated as news breaks.
Updated February 2026
Switching to Retatrutide from Tirzepatide or Semaglutide
Retatrutide is not yet available, but here is what we know about switching between GLP-1 drugs and how to access clinical trials.
Updated February 2026
Retatrutide and Fatty Liver Disease (MASLD/MASH)
Retatrutide produced up to 82.4% liver fat reduction in Phase 2 — among the strongest results for any drug in development for MASLD/MASH.
Updated February 2026
Retatrutide for Type 2 Diabetes
Retatrutide's Phase 2 T2D data showed HbA1c reductions of -2.02% and weight loss of -16.94% — with the TRANSCEND Phase 3 program underway.
Updated February 2026
Does Retatrutide Cause Muscle Loss?
The first DXA body composition data for retatrutide, the glucagon muscle-sparing hypothesis, and evidence-based strategies to preserve lean mass.
Updated February 2026
Retatrutide and Sleep Apnea (Obstructive Sleep Apnea)
No retatrutide OSA data yet, but the TRIUMPH-1 nested sub-study and tirzepatide's precedent point to substantial potential.
Updated February 2026
Retatrutide for Obesity and Knee Osteoarthritis
TRIUMPH-4 showed 28.7% weight loss and 75.8% pain reduction in adults with obesity and knee osteoarthritis.
Updated February 2026
Retatrutide Pill vs Injection: Is There an Oral Formulation?
Retatrutide is injection-only. Here's why there's no pill, how the injection works, and how oral GLP-1 alternatives compare.
Updated February 2026
Retatrutide Results: Weight Loss Data and What to Expect
28.7% average weight loss in Phase 3 — here's the full data breakdown by dose, timeline, and what individual results look like.
Updated February 2026
Retatrutide Dosing Calculator & Schedule
Interactive dose escalation timeline, reconstitution calculator, weight loss by dose level, and when to hold a dose increase.
Updated February 2026
Retatrutide Results: Before and After — What the Data Actually Shows
No real before/after photos exist. Here's what the clinical trial data shows: 28.7% average weight loss at 68 weeks, month-by-month breakdown.
Updated February 2026
Retatrutide vs Wegovy: Triple Agonist vs GLP-1
Retatrutide produces nearly double the weight loss of Wegovy, but Wegovy is available now with proven cardiovascular protection.
Updated February 2026
Retatrutide vs Zepbound: What's the Difference?
Same manufacturer, different drugs. Retatrutide adds glucagon agonism for 28.7% vs Zepbound's 22.5% weight loss.
Updated February 2026
How to Reconstitute Retatrutide (and Why You Shouldn't)
Pharmaceutical retatrutide does not require reconstitution — it comes pre-filled. Grey market powder reconstitution is dangerous.
Updated February 2026
How to Sign Up for a Retatrutide Clinical Trial
The only way to access retatrutide in 2026 is through clinical trials. Here's how to find and enroll in a TRIUMPH trial.
Updated February 2026
Retatrutide Brand Name: What Will It Be Called?
Eli Lilly hasn't announced a brand name for retatrutide yet. Expect it close to FDA approval in 2027.
Updated February 2026
Retatrutide Half-Life and Pharmacokinetics
Retatrutide has a ~6-day half-life achieved through fatty acid albumin binding — comparable to semaglutide (~7 days) and tirzepatide (~5 days).
Updated February 2026
How to Inject Retatrutide
Once-weekly subcutaneous injection using a pre-filled pen. Same technique as Mounjaro — here's the step-by-step guide.
Updated February 2026
When Will Retatrutide Be Available?
Retatrutide is not yet available. NDA expected Q4 2026, FDA approval projected Q3-Q4 2027, commercial launch Q4 2027 or early 2028.
Updated February 2026
How Does Retatrutide Work? Mechanism of Action Explained
The world's first triple agonist explained — how GLP-1, GIP, and glucagon receptors work together to reduce appetite and increase energy expenditure.
Updated February 2026
Retatrutide vs Tirzepatide (Zepbound): Triple Agonist vs Dual Agonist
Retatrutide produces 28.7% weight loss (triple agonist) vs tirzepatide's 22.5% (dual agonist). A head-to-head trial is underway.
Updated February 2026
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Grey market retatrutide is unregulated, untested, and potentially dangerous. Here's what the data shows and how to access it safely.
Updated February 2026
How to Pronounce Retatrutide
Retatrutide is pronounced reh-TAT-roo-tide (/rɪˈtætrʊtaɪd/). Here's the full breakdown plus other obesity drug pronunciations.
Updated February 2026
Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo
Cagrilintide vs retatrutide: triple agonist vs amylin + GLP-1 combo — 28.7% vs 22.7% weight loss, different receptors, and stacking considerations.
Updated February 2026
CagriSema vs Tirzepatide (Zepbound): REDEFINE 4 Head-to-Head Results
CagriSema lost to tirzepatide in REDEFINE 4: 23.0% vs 25.5% weight loss at 84 weeks. Retatrutide achieved 28.7% in TRIUMPH-4.
Updated February 2026
Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist
Cagrilintide + tirzepatide stacking: no human trial data, CagriSema lost to tirzepatide in REDEFINE 4, and retatrutide offers 28.7% weight loss from one molecule.
Updated February 2026
What Is Cagrilintide? The Amylin Analog Behind CagriSema
Novo Nordisk's long-acting amylin analog — 11.5% weight loss as monotherapy, and the key ingredient in CagriSema.
Updated February 2026
What Is CagriSema? Novo Nordisk's Amylin + GLP-1 Weight Loss Combination
Novo Nordisk's amylin + GLP-1 combination — 20.4% weight loss in REDEFINE 1, NDA filed December 2025.
Updated February 2026
What Is Orforglipron? Lilly's Oral GLP-1 Weight Loss Pill
Eli Lilly's oral GLP-1 pill — 12.4% weight loss, no injections, no fasting. Filed for FDA approval in 40+ countries.
Updated February 2026
What Is Survodutide? The Dual GLP-1/Glucagon Agonist for Weight Loss and MASH
Boehringer Ingelheim's dual GLP-1/glucagon agonist — 18.7% weight loss in Phase 2, 83% MASH resolution, Phase 3 ongoing.
Updated February 2026
What Is Mazdutide (Xinermei)? The First GLP-1/Glucagon Drug Approved in China
The first GLP-1/glucagon dual agonist approved anywhere — how it works, what the trials show, and why it matters for the obesity drug landscape.
Updated February 2026
Mazdutide vs Tirzepatide: GLP-1/Glucagon vs GLP-1/GIP Compared
Mazdutide pairs GLP-1 with glucagon for liver fat clearance. Tirzepatide pairs GLP-1 with GIP for maximum appetite suppression. Different second receptors, different strengths.
Updated February 2026
Orforglipron vs Tirzepatide (Zepbound): Oral Pill vs Weekly Injection
Orforglipron offers 12.4% weight loss as a daily pill. Tirzepatide delivers 22.5% as a weekly injection. Both are from Eli Lilly.
Updated February 2026
Orforglipron vs Zepbound (Tirzepatide): Daily Pill vs Weekly Injection
Orforglipron offers 12.4% weight loss as a daily pill starting at $149/month. Zepbound delivers 22.5% as a weekly injection at $299-$449/month. Both from Eli Lilly.
Updated March 2026
Survodutide vs Tirzepatide (Zepbound): Glucagon vs GIP as the Second Target
Survodutide adds glucagon for energy expenditure and liver fat. Tirzepatide adds GIP for insulin and appetite. Different second receptors, different strengths.
Updated February 2026
Retatrutide vs Orforglipron: Injectable Triple Agonist vs Oral GLP-1
Retatrutide produces 28.7% weight loss via injection. Orforglipron offers 12.4% weight loss as a daily pill. Both are from Eli Lilly.
Updated February 2026
Microdosing Retatrutide & GLP-1 Drugs: What the Research Shows
Current evidence on sub-therapeutic dosing and dose-splitting of GLP-1 receptor agonists.
Updated February 2026
Retatrutide and Heart Health (Cardiovascular Effects)
Early data shows improvements in blood pressure, lipids, and inflammation. Dedicated cardiovascular outcomes trials are underway.
Updated February 2026
Zepbound vs Wegovy: Which Weight Loss Drug Is Better?
Zepbound produced -20.2% vs Wegovy's -13.7% weight loss in the SURMOUNT-5 head-to-head trial. Full comparison of cost, side effects, and CV data.
Updated February 2026
Tirzepatide vs Semaglutide: Complete Comparison (2026 Data)
Tirzepatide vs semaglutide with SURMOUNT-5 head-to-head data: -20.2% vs -13.7% weight loss. Full comparison of efficacy, side effects, and access.
Updated February 2026
Mounjaro vs Ozempic: Which Is Better for Weight Loss and Diabetes?
Mounjaro produced twice the weight loss of Ozempic in head-to-head trials. Practical comparison of cost, insurance, and prescribing differences.
Updated February 2026
Ozempic vs Wegovy: Same Drug, Different Purpose
Ozempic and Wegovy both contain semaglutide. The difference: indication (diabetes vs weight loss), max dose (2.0 vs 2.4 mg), and insurance coverage.
Updated February 2026
GLP-1 Drug Comparison Tool: Compare Weight Loss Drugs Side by Side
Interactive comparison tool for GLP-1 weight loss drugs. Select 2-3 drugs to compare mechanism, efficacy, cost, and status.
Updated February 2026
Which GLP-1 Drug Is Best for Weight Loss? (2026 Guide)
Decision framework for choosing the best GLP-1 drug: by max weight loss, CV protection, oral option, diabetes control, or liver fat.
Updated February 2026
Coach Gary Miller on Retatrutide: His Protocol vs What the Data Shows
Gary Miller's retatrutide protocol fact-checked against Phase 2 and Phase 3 clinical data.
Updated February 2026
Adrian Crook Quit Retatrutide After 6 Months: What He Learned
A 6-month retatrutide diary with DEXA data, craving elimination, and a PPI interaction warning.
Updated February 2026
Dr. Alex Tatem on Retatrutide: A Physician's Breakdown Fact-Checked
A physician's retatrutide explainer fact-checked — mechanism, Phase 2 data, drug comparisons, and FDA timeline.
Updated February 2026
Nick Trigili on Retatrutide: His 10-Week Protocol vs What the Data Shows
Trigili's 10-week retatrutide protocol fact-checked against TRIUMPH-4 clinical trial data.
Updated February 2026
David DeMesquita's Retatrutide Injection Guide: What He Shows and What You Should Know
DeMesquita's retatrutide reconstitution and injection video analyzed with safety context.
Updated February 2026
Coach Colin Watson on Retatrutide: 12-Week Review vs What the Data Shows
Colin Watson's 12-week retatrutide review fact-checked — garbled mechanism, unsupported set point claims, and a peptide seller conflict of interest.
Updated February 2026
Dr. Kevin Joseph on Retatrutide: Physician's Overview Fact-Checked
Dr. Kevin Joseph's retatrutide overview fact-checked — solid mechanism explanation, a few errors on trial data, and side effect predictions contradicted by Phase 3.
Updated February 2026
Dave Nap on CagriSema vs Tirzepatide, Novo Nordisk's Triple Agonist UBT-251, and Retatrutide: Fact Check
On The Pen host Dave Nap on CagriSema vs tirzepatide, Novo Nordisk triple agonist UBT-251, and retatrutide — fact-checked.
Updated February 2026
JD Denham on Retatrutide: Triple Agonist Mechanism, Dosing, and Fat Loss Claims — Fact Check
Peptide of the Week hosts on retatrutide dosing, nausea, muscle loss, and fat burning — fact-checked against clinical data.
Updated February 2026
Andrew Huberman on Retatrutide: What He Said and What the Data Shows
Huberman called retatrutide 'the peptide that changes everything.' Here's what he said and what the data actually shows.
Updated February 2026
The Peptide Advantage Retatrutide Dosing Protocol: Fact Check
The Peptide Advantage's 3x/week retatrutide microdosing protocol contradicts all clinical trial data — fact-checked.
Updated February 2026
Michael Morelli on Retatrutide: Fact Check
Michael Morelli claims retatrutide is anabolic and boosts cognition — fact-checked against published data.
Updated February 2026
Dr. Dan on Retatrutide vs Ozempic: Obesity Expert Fact Check
Obesity expert Dr. Dan's retatrutide vs Ozempic comparison — Phase 2 data, side effects, and timeline predictions fact-checked.
Updated February 2026
Retatrutide vs AOD-9604: Triple Agonist vs Growth Hormone Fragment
Retatrutide produced 28.7% weight loss in Phase 3 trials. AOD-9604 failed its largest trial. Here's how they compare.
Updated March 2026
Peptides for Weight Loss vs GLP-1 Drugs: What the Evidence Says
GLP-1 drugs have Phase 3 trials and FDA approval. Research peptides have failed trials and animal data. The full evidence comparison.
Updated March 2026
Are Peptides Legal in 2026? The FDA Reclassification Explained
RFK announced 14 banned peptides returning to legal compounding. What it means, which peptides, and how it affects weight loss drugs.
Updated March 2026
What Is Amycretin? Novo Nordisk's Oral GLP-1/Amylin Weight Loss Drug
Novo Nordisk's first-in-class GLP-1/amylin dual agonist — 13.1% weight loss as a daily pill in 12 weeks, 22% as a weekly injection in 36 weeks.
Updated March 2026
Dr. Jones DC on Retatrutide Phase 3 Results (28.7% Weight Loss), Triple Agonist Mechanism, and Retatrutide vs Tirzepatide: Fact Check
Dr. Jones DC on retatrutide Phase 3 results, triple agonist mechanism, and retatrutide vs tirzepatide — fact-checked against trial data.
Updated February 2026
Retatrutide and Food Noise: How Triple Agonism Quiets Cravings
How retatrutide's three receptors each contribute a distinct mechanism to reducing food noise, and what the Phase 2 data shows.
Updated March 2026
Weight Loss Drugs and Hair Loss: What Retatrutide's 24% Weight Loss Means
More weight loss means more hair shedding. Retatrutide's 24% weight loss likely puts it at the top — here's the clinical data and what to do about it.
Updated March 2026
What Is Pemvidutide? Altimmune's GLP-1/Glucagon Dual Agonist for Weight Loss and MASH
Altimmune's balanced GLP-1/glucagon dual agonist — 15.6% weight loss, 54.7% liver fat reduction, FDA Breakthrough Therapy Designation for MASH.
Updated March 2026
Retatrutide and Pregnancy: What Triple Agonism Means for Fertility and Safety
Three receptors, three pregnancy concerns. What GLP-1, GIP, and glucagon receptor research means for retatrutide and reproductive safety.
Updated March 2026
GLP-1 Drugs and Mental Health: What the Evidence Actually Shows
The FDA cleared GLP-1 drugs of psychiatric risk after reviewing 91 trials. The surprising finding: these drugs may actually improve depression.
Updated March 2026
Retatrutide for Women: What the Clinical Data Shows
What women need to know about retatrutide — side effects by sex, birth control interactions, fertility, hair loss, PCOS potential, and body composition.
Updated March 2026
Mazdutide vs Survodutide: Two GLP-1/Glucagon Dual Agonists Compared
Both target GLP-1 and glucagon, but mazdutide is approved in China with best-in-class tolerability while survodutide leads on MASH liver data.
Updated March 2026
Orforglipron vs Rybelsus (Oral Semaglutide): Two Oral GLP-1 Pills Compared
Orforglipron has no food restrictions and beat Rybelsus on weight loss in ACHIEVE-3. Rybelsus requires fasting but is available now.
Updated March 2026
GLP-3 Wiki is an independent informational resource. We are not affiliated with Eli Lilly, Novo Nordisk, or any pharmaceutical company. Retatrutide is an investigational drug that has not been approved by the FDA. This site is not medical advice. Always consult a healthcare provider before making decisions about medication.